As reported by the PharmaTimes, the contract research organisation (CRO), Novella Clinical has acquired the US CRO Prologue Research International. The deal will add some 60 pharmaceutical jobs to the already 738 strong team.
Prologue mainly focuses on cancer drug development, so the deal will see Novella Clinical’s oncology profile rise significantly. In fact, Richard Staub, Novella’s CEO has been quoted in saying that the acquisition is a welcome ‘strategic addition’ to the clinical services agreement signed earlier this year with OSI Pharmaceuticals.
OSI Pharmaceuticals mainly focuses on discovering, developing and commercialising targeted medicines for cancer. In January, Novella and OSI expanded their clinical services, meaning that Novella had the capability to provide clinical research to SE for a two-year period.
With the acquisition of Prologue, Novella Clinical will now create a business unit dedicated to oncology drug development.
Speaking of the acquisition, Tom Ludham, CEO of Prologue said that it: “allows us to better serve current and future customers in the design and execution of complex oncology programmes across geographic regions”.
Looking for a job in the clinical research industry? Click here to search our current clinical research jobs.